TMPRSS2-ERG and PTEN loss in prostate cancer
- PMID: 19399032
- DOI: 10.1038/ng0509-509
TMPRSS2-ERG and PTEN loss in prostate cancer
Abstract
Two studies show that the common recurrent gene fusion between TMPRSS2 and ERG promotes prostate cancer in both mouse and humans when PTEN is concurrently lost. In human prostate cancer, the presence of both these aberrations may be indicative of poor prognosis, suggesting that preclinical therapeutic research should target both of these pathways.
Comment on
-
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.Nat Genet. 2009 May;41(5):524-6. doi: 10.1038/ng.371. Epub 2009 Apr 26. Nat Genet. 2009. PMID: 19396167 Free PMC article.
-
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.Nat Genet. 2009 May;41(5):619-24. doi: 10.1038/ng.370. Epub 2009 Apr 26. Nat Genet. 2009. PMID: 19396168 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
